Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal scopolamine in motion sickness.

C M Cronin, S E Sallan, L Wolfe

    Pharmacotherapy
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A novel test for determination of wild felid-domestic cat hybridization.

    Forensic science international. Genetics·2019
    Same author

    Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.

    International journal of laboratory hematology·2018
    Same author

    Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.

    Pediatric blood & cancer·2018
    Same author

    Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.

    The pharmacogenomics journal·2016
    Same author

    Circadian timing and alignment in healthy adults: associations with BMI, body fat, caloric intake and physical activity.

    International journal of obesity (2005)·2016
    Same author

    Transplacental passage of clindamycin from mother to neonate.

    Journal of perinatology : official journal of the California Perinatal Association·2016
    Same journal

    Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

    Pharmacotherapy·2026
    Same journal

    Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

    Pharmacotherapy·2026
    Same journal

    The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

    Pharmacotherapy·2026
    Same journal

    Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

    Pharmacotherapy·2026
    Same journal

    Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

    Pharmacotherapy·2026
    Same journal

    Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

    Pharmacotherapy·2026
    See all related articles

    Transdermal therapeutic systems (TTS) offer a new way to manage motion sickness. This scopolamine delivery method provides consistent drug levels, improving patient outcomes and reducing side effects from oral medications.

    Area of Science:

    • Pharmacology
    • Gastroenterology
    • Drug Delivery Systems

    Background:

    • Motion sickness is a prevalent condition causing nausea and vomiting.
    • Traditional oral scopolamine administration can lead to unpredictable blood levels and side effects.
    • The short half-life of scopolamine necessitates frequent dosing with conventional methods.

    Purpose of the Study:

    • To introduce and evaluate a novel transdermal therapeutic system (TTS) for scopolamine delivery.
    • To assess the efficacy of TTS in maintaining therapeutic drug concentrations for motion sickness.
    • To compare the safety and patient acceptability of TTS with oral scopolamine formulations.

    Main Methods:

    • Development of a transdermal therapeutic system (TTS) for continuous scopolamine release.

    Related Experiment Videos

  • Administration of scopolamine via TTS to maintain stable blood concentrations.
  • Monitoring of patient compliance and adverse effects associated with TTS compared to oral dosage.

    • Main Results:

    • The TTS delivers scopolamine at a constant rate across the skin.
    • Stable therapeutic blood levels of scopolamine are maintained over prolonged periods.
    • Reduced incidence of side effects and improved patient compliance were observed with TTS.

    Conclusions:

    • Transdermal therapeutic systems provide a superior method for administering scopolamine for motion sickness.
    • TTS technology minimizes side effects by ensuring predictable drug absorption and stable blood levels.
    • This new delivery system enhances patient acceptability and compliance for motion sickness treatment.